A importância do gene p53 na carcinogênese humana

Fett‐Conte, Agnes Cristina; Salles, Andréa B.C.F.

doi:10.1590/s1516-84842002000200004

Cited by 14 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…), and anti‐apoptotic ( BCL‐2 itself, BCL‐XL and BCL‐W ) processes . Because BCL‐2 overexpression was identified in B cell malignancies, it has been observed in different types of tumours and cell lines in both humans and other animals . Its involvement in cancer has also been determined .…”

Section: Introductionmentioning

confidence: 99%

Cell cycle kinetics, apoptosis rates and gene expressions of MDR‐1, TP53, BCL‐2 and BAX in transmissible venereal tumour cells and their association with therapy response

Flórez

Fêo

Silva

et al. 2016

Vet Comparative Oncology

View full text Add to dashboard Cite

Transmissible venereal tumour (TVT) generally presents different degrees of aggressiveness, which makes them unresponsive to conventional treatment protocols. This implies a progressive alteration of their biological profile. This study aimed to evaluate the cytotoxicity, cell survival, apoptosis and cell cycle alterations in TVT cell cultures subjected to treatment with vincristine. Similarly, it assessed possible implications of MDR-1, TP53, BCL-2, and BAX gene expressions in eight TVT primary cultures for both resistance to chemotherapy and biological behaviour. When comparing TVT cells receiving vincristine to those untreated, a statistical difference related to increased cytotoxicity and decreased survival rates, and alterations in G1 and S cell cycle phases were found but without detectable differences in apoptosis. Increased MDR-1 gene expression was observed after treatment. The groups did not differ statistically in relation to the TP53, BAX and BCL-2 genes. Although preliminary, the findings suggest that such augmented expression is related to tumour malignancy and chemotherapy resistance.

show abstract

Section: Introductionmentioning

confidence: 99%

Cell cycle kinetics, apoptosis rates and gene expressions of MDR‐1, TP53, BCL‐2 and BAX in transmissible venereal tumour cells and their association with therapy response

Flórez

Fêo

Silva

et al. 2016

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…As a result of punctual mutations, the protein, with its morphofunctional aspects affected, may become inactive or play abnormal roles, such as the loss of responsiveness of the cycle control, inability to promote the activation of DNA repair genes, senescence and cell apoptosis, contributing thus to neoplastic progression (CALAZANS et al, 2010). Also as a result of these changes, p53 is unable to activate the MDM2 protein and, thus, its half-life remains increased (FETT-CONT & SALLES, 2002;ECKE et al, 2005).…”

Section: Major P53 Gene Mutationsmentioning

confidence: 99%

“…The confirmation that inactive or defective genes responsible for certain illness could be replaced by functional genes has revolutionized the base of the antineoplastic therapeutic research (FETT-CONT & SALLES, 2002;LEE et al, 2009).…”

Section: Anticancer Therapy and P53mentioning

confidence: 99%

“…Currently, researchers are studying the gene therapy as a control measure of the resistance of neoplastic cells to apoptosis (TANG et al, 2011;YOSHIOKA et al, 2011). The p53 centrality in neoplastic processes stimulates the search for an anticancer therapy model from this gene (FETT-CONT & SALLES, 2002;ZENG et al, 2011). Various strategies can be adopted for discovery of mutant p53 -reactivating compounds (FARNEBO et al, 2010;SCHNEIDER & KRÄMER, 2011;TANG et al, 2011).…”

Section: Anticancer Therapy and P53mentioning

confidence: 99%

See 1 more Smart Citation

P53 gene: major mutations in neoplasias and anticancer gene therapy

et al. 2012

View full text Add to dashboard Cite

show abstract

“…This tumor suppressor gene is one of the most important genes of tumorigenesis because mutations in this gene exist in more than 50% of all cancers [5,6]. Such mutations often result in the overexpression of p53 protein containing alterations that impede its normal function [3].…”

Section: Introductionmentioning

confidence: 99%